Transferrin Receptor Shows Promise as Iron Marker in IBD
A study has found that soluble transferrin receptor (sTfR) levels can serve as an inflammation-independent marker of iron status in patients with inflammatory bowel disease (IBD). The research included 411 patients with IBD and 178 healthy controls, highlighting the potential of sTfR to distinguish true iron deficiency from inflammation-related changes. The findings suggest that sTfR may be a valuable complement to conventional iron assessment methods in IBD patients.
- ▪Soluble transferrin receptor levels showed no correlation with C-reactive protein or faecal calprotectin levels in IBD patients.
- ▪Patients with ulcerative colitis and iron deficiency without anaemia had higher median sTfR levels compared to those without iron deficiency.
- ▪The study was led by Francisco Portela from the Portuguese Inflammatory Bowel Disease Study Group and published in Inflammatory Bowel Diseases.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Soluble transferrin receptor (sTfR) levels appeared to function as an inflammation-independent marker of iron status in patients with inflammatory bowel disease (IBD) and may help distinguish true iron deficiency from inflammation-related changes in iron parameters.METHODOLOGY:Researchers conducted a cross-sectional study to evaluate the utility of sTfR levels in assessing iron status in patients with IBD and identifying iron deficiency without anaemia (IDWA).They included 411 patients with IBD, of whom 130 had ulcerative colitis (UC; median age, 44 years; 61.24% women) and 281 had Crohn's disease (median age, 41 years; 46.98% women); they also included 178 healthy control individuals, and outcomes were compared between groups.IDWA was defined using ferritin thresholds (< 30 ng/mL…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
